SolasCure, a Cambridge biotech developing a novel treatment to transform chronic wound healing, has initiated a new Phase II ...

SolasCure has initiated a new Phase II clinical trial, CLEANVLU2, to further the development of its investigational product, ...

The gel is designed to be a 'safe' debrider suitable ... in addressing all aspects of wound bed preparation, including debridement. As part of the community service, the trial is being conducted ...

This trial will generate key efficacy data to further demonstrate Aurase Wound Gel's potential as the first treatment to ...

Phase II clinical trial to determine the efficacy of Aurase Wound Gel at a higher concentration of the active enzyme Tarumase in venous leg ulcers SOLASCURE Ltd (SolasCure), a biotechnology company ...